Siu Chung-Wah, Zhang Xue-Hua, Yung Cindy, Kung Annie W C, Lau Chu-Pak, Tse Hung-Fat
Cardiology Division, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
J Clin Endocrinol Metab. 2007 May;92(5):1736-42. doi: 10.1210/jc.2006-1877. Epub 2007 Feb 27.
Recent reports suggest an association between hyperthyroidism and pulmonary hypertension (PHT), although the potential mechanisms and clinical implications remain unclear.
Our objective was to determine the prevalence of PHT related to hyperthyroidism and the associated hemodynamic changes and outcome.
We performed serial echocardiographic examinations in 75 consecutive patients with hyperthyroidism (43 +/- 2 yr, 47 women) to estimate pulmonary artery systolic pressure (PASP), cardiac output (CO), total vascular resistance (TVR), and left ventricular (LV) filling pressure. Examinations were performed at baseline and 6 months after initiation of antithyroid treatment. Results were compared with 35 age- and sex-matched healthy controls. All hyperthyroid patients had normal LV systolic function, and 35 patients (47%) had PHT with PASP of at least 35 mm Hg. There were no significant differences in the clinical characteristics of hyperthyroid patients with or without PHT (all P > 0.05). Nonetheless, those with PHT had significantly higher CO, PASP, peak transmitral early diastolic flow velocity (E), and ratio of E to early diastolic mitral annular velocity (E') compared with those without PHT and controls (all P < 0.05). Hyperthyroid patients with PHT also had significantly lower TVR than controls (P < 0.05). Among the 35 hyperthyroid patients with PHT, 25 (71%) had pulmonary arterial hypertension (PAH) with normal E/E', and 10 (29%) had pulmonary venous hypertension (PVH) with elevated E/E'. Hyperthyroid patients with PAH had a significantly higher CO and a lower TVR compared with those with PVH. In contrast, hyperthyroid patients with PVH had lower E' and a higher E/E' ratio compared with those with PAH. These hemodynamic abnormalities and PHT were reversible in patients with PAH or PVH after restoration to a euthyroid state.
In patients with hyperthyroidism and normal LV systolic function, up to 47% had PHT due to either PAH with increased CO (70%) or PVH with elevated LV filling pressure (30%). Most importantly, hyperthyroidism-related PHT was largely asymptomatic and reversible after restoration to a euthyroid state.
近期报告提示甲状腺功能亢进症与肺动脉高压(PHT)之间存在关联,但其潜在机制及临床意义仍不明确。
我们的目的是确定与甲状腺功能亢进症相关的PHT的患病率以及相关的血流动力学变化和结局。
我们对75例连续的甲状腺功能亢进症患者(43±2岁,47例女性)进行了系列超声心动图检查,以评估肺动脉收缩压(PASP)、心输出量(CO)、总血管阻力(TVR)和左心室(LV)充盈压。在基线时以及开始抗甲状腺治疗6个月后进行检查。将结果与35例年龄和性别匹配的健康对照者进行比较。所有甲状腺功能亢进症患者的左心室收缩功能均正常,35例患者(47%)患有PHT,PASP至少为35mmHg。有或无PHT的甲状腺功能亢进症患者的临床特征无显著差异(所有P>0.05)。尽管如此,与无PHT的患者及对照者相比,有PHT的患者的CO、PASP、二尖瓣舒张早期血流峰值速度(E)以及E与二尖瓣环舒张早期速度之比(E')显著更高(所有P<0.05)。有PHT的甲状腺功能亢进症患者的TVR也显著低于对照者(P<0.05)。在35例有PHT的甲状腺功能亢进症患者中,25例(71%)患有肺动脉高压(PAH)且E/E'正常,10例(29%)患有肺静脉高压(PVH)且E/E'升高。与患有PVH的患者相比,患有PAH的甲状腺功能亢进症患者的CO显著更高,TVR更低。相反,与患有PAH的患者相比,患有PVH的甲状腺功能亢进症患者的E'更低,E/E'比值更高。在恢复到甲状腺功能正常状态后,患有PAH或PVH的患者的这些血流动力学异常和PHT是可逆的。
在左心室收缩功能正常的甲状腺功能亢进症患者中,高达47%的患者因CO增加的PAH(70%)或左心室充盈压升高的PVH(30%)而患有PHT。最重要的是,与甲状腺功能亢进症相关的PHT在很大程度上无症状,且在恢复到甲状腺功能正常状态后是可逆的。